Match!
Jessica Stoll
University of Chicago
15Publications
3H-index
25Citations
Publications 16
Newest
Source
#1Nina Beri (UPenn: University of Pennsylvania)H-Index: 1
#2Linda Patrick-Miller (U of C: University of Chicago)H-Index: 16
Last.Angela R. Bradbury (UPenn: University of Pennsylvania)H-Index: 15
view all 33 authors...
2 CitationsSource
#1Charles Muller (U of C: University of Chicago)H-Index: 2
#2Sang Mee Lee (U of C: University of Chicago)H-Index: 1
Last.Sonia S. Kupfer (U of C: University of Chicago)H-Index: 20
view all 14 authors...
Background & Aims Guidelines recommend that all colorectal tumors be assessed for mismatch repair deficiency, which could increase identification of patients with Lynch syndrome. This is of particular importance for minority populations, in whom hereditary syndromes are under diagnosed. We compared rates and outcomes of testing all tumor samples (universal testing) collected from a racially and ethnically diverse population for features of Lynch syndrome. Methods We performed a retrospective ana...
3 CitationsSource
#1Michael J. HallH-Index: 4
Last.A. R. BradburyH-Index: 9
view all 32 authors...
PurposeMultigene panels (MGPs) are increasingly being used despite questions regarding their clinical utility and no standard approach to genetic counseling. How frequently genetic providers use MGP testing and how patient-reported outcomes (PROs) differ from targeted testing (eg, BRCA1/2 only) are unknown.MethodsWe evaluated use of MGP testing and PROs in participants undergoing cancer genetic testing in the multicenter Communication of Genetic Test Results by Telephone study (ClinicalTrials.go...
Source
#1Allison H. West (U of C: University of Chicago)H-Index: 4
#2Kathleen R. Blazer (Beckman Research Institute)H-Index: 20
Last.Olufunmilayo I. Olopade (U of C: University of Chicago)H-Index: 81
view all 9 authors...
Comprehensive genomic cancer risk assessment (GCRA) helps patients, family members, and providers make informed choices about cancer screening, surgical and chemotherapeutic risk reduction, and genetically targeted cancer therapies. The increasing availability of multigene panel tests for clinical applications allows testing of well-defined high-risk genes, as well as moderate-risk genes, for which the penetrance and spectrum of cancer risk are less well characterized. Moderate-risk genes are de...
Source
#1Angela R. Bradbury (UPenn: University of Pennsylvania)H-Index: 15
#2Linda Patrick-Miller (U of C: University of Chicago)H-Index: 16
Last.Xinxin (Shirley) Yao (University of Texas MD Anderson Cancer Center)H-Index: 1
view all 32 authors...
7 CitationsSource
#1David A. Chambers (NIH: National Institutes of Health)H-Index: 22
#2Lisa Simpson MBBCh Mph (AcademyHealth)H-Index: 23
Last.James Teufel (Mercyhurst University)H-Index: 8
view all 372 authors...
A1 Introduction to the 8th Annual Conference on the Science of Dissemination and Implementation: Optimizing Personal and Population Health
7 CitationsSource
#1Charles MullerH-Index: 2
#2William BargeH-Index: 2
Last.Sonia S. KupferH-Index: 20
view all 7 authors...
Source
#1Matthew W. Stier (U of C: University of Chicago)H-Index: 2
#2Jessica Stoll (U of C: University of Chicago)H-Index: 3
Last.Sonia S. Kupfer (U of C: University of Chicago)H-Index: 20
view all 3 authors...
Source
12